ALK and neuroblastoma: Another ALK inhibitor, ensartinib, has entered clinical trials of patients with non‐Hodgkin's lymphoma, relapsed or refractory NB, or histiocytic disorders with ROS1 or ALK genomic alterations (NCT03213652).